Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nina Raulf

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Therapeutic Delivery|March 27, 2019
Developing small activating RNA as a therapeutic: current challenges and promisesAlbert Kwok, Nina Raulf, Nagy Habib
Molecular Oncology|July 1, 2018
MicroRNA-9 inhibits growth and invasion of head and neck cancer cells and is a predictive biomarker of response to plerixafor, an inhibitor of its target CXCR4Hersi Mohamed Hersi, Nina Raulf, Joop Gaken, et al.
Nucleic Acids Research|February 4, 2010
NIR, an inhibitor of histone acetyltransferases, regulates transcription factor TAp63 and is controlled by the cell cycleKristina Heyne, Vivienne Willnecker, Julia Schneider, et al.
Cell Death & Disease|July 17, 2019
Clinical update on head and neck cancer: molecular biology and ongoing challengesElham Alsahafi, Katheryn Begg, Ivano Amelio, et al.
The Journal of Biological Chemistry|January 27, 2012
Cytosolic Bax: does it require binding proteins to keep its pro-apoptotic activity in check?Sandra Vogel, Nina Raulf, Stephanie Bregenhorn, et al.
International Journal of Cancer|December 20, 2014
MicroRNA-196a promotes an oncogenic effect in head and neck cancer cells by suppressing annexin A1 and enhancing radioresistanceYae-Eun Suh, Nina Raulf, Joop Gäken, et al.
Frontiers in Medicine|May 25, 2026
RNA activation as a precision dosing modality: MTL-CEBPA for controlled enzyme elevation in MPS I-HVikash Reebye, Konstantina Skourti-Stathaki, Konstantinos Vanezis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2021
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with CancerAyumi Hashimoto, Debashis Sarker, Vikash Reebye, et al.
Cell Reports. Medicine|April 1, 2025
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Mikael H Sodergren, Rose Hodgson, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Therapeutic Delivery|March 27, 2019
Developing small activating RNA as a therapeutic: current challenges and promisesAlbert Kwok, Nina Raulf, Nagy Habib
Molecular Oncology|July 1, 2018
MicroRNA-9 inhibits growth and invasion of head and neck cancer cells and is a predictive biomarker of response to plerixafor, an inhibitor of its target CXCR4Hersi Mohamed Hersi, Nina Raulf, Joop Gaken, et al.
Nucleic Acids Research|February 4, 2010
NIR, an inhibitor of histone acetyltransferases, regulates transcription factor TAp63 and is controlled by the cell cycleKristina Heyne, Vivienne Willnecker, Julia Schneider, et al.
Cell Death & Disease|July 17, 2019
Clinical update on head and neck cancer: molecular biology and ongoing challengesElham Alsahafi, Katheryn Begg, Ivano Amelio, et al.
The Journal of Biological Chemistry|January 27, 2012
Cytosolic Bax: does it require binding proteins to keep its pro-apoptotic activity in check?Sandra Vogel, Nina Raulf, Stephanie Bregenhorn, et al.
International Journal of Cancer|December 20, 2014
MicroRNA-196a promotes an oncogenic effect in head and neck cancer cells by suppressing annexin A1 and enhancing radioresistanceYae-Eun Suh, Nina Raulf, Joop Gäken, et al.
Frontiers in Medicine|May 25, 2026
RNA activation as a precision dosing modality: MTL-CEBPA for controlled enzyme elevation in MPS I-HVikash Reebye, Konstantina Skourti-Stathaki, Konstantinos Vanezis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2021
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with CancerAyumi Hashimoto, Debashis Sarker, Vikash Reebye, et al.
Cell Reports. Medicine|April 1, 2025
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Mikael H Sodergren, Rose Hodgson, et al.
Pageof 1